By

Lundbeckfonden
SAN DIEGO – January 8, 2018 – Amplyx Pharmaceuticals, a company developing first-in-class products for life-threatening infections, with a near-term focus on deadly fungal pathogens, today announced that Alan Fuhrman has been appointed as Chief Financial Officer of Amplyx. The Company also announced today that Ciara Kennedy, Ph.D., Chief Executive Officer of Amplyx, will present...
Palma, Spain, and San Diego, USA, January 8, 2018 – Laboratoris Sanifit S.L., a clinical-stage biopharmaceutical company focused on treatments for calcification disorders, today announced the appointment of Cris Calsada as Chief Financial Officer. Ms. Calsada joins Sanifit with over 20 years of corporate finance and executive experience in the life sciences and technology industries....
PARIS and CAMBRIDGE, Massachusetts, January 4, 2018 /PRNewswire/ — – Proceeds will be used to progress lead development programs – EB8018 for IBD and EO2315 for cancer – Secures €40 million loan facility ($48 million) from the European Investment Bank ENTEROME SA, a clinical-stage biotech company pioneering innovative therapies to treat microbiome-associated diseases with a focus on inflammatory bowel diseases (IBD) and immuno-oncology (IO) indications, announces that it...
If approved, BAREMSIS would be the first antiemetic with an indication for: –       rescue treatment of PONV after failed prophylaxis, and –       combination prophylaxis of PONV with standard antiemetics Cambridge, UK and Indianapolis, US – 4th January 2018: Acacia Pharma Group Ltd (“Acacia Pharma”), a pharmaceutical company developing and commercialising hospital products for US and...
A large international team of scientists has retrieved the entire DNA from an 11,500-year-old skeleton of a child from Alaska. Their finding has just been published in Nature. This discovery pushes the date of the first migration to the American continent back by 10,000 years. It also shows that, at one point, the Native Americans...
Lead candidate, light-activated AU-011, currently being investigated in Phase 1b/2 study to treat ocular melanoma, an orphan indication Funding to support ongoing clinical development, enabling buildout of company infrastructure and GMP manufacturing CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aura Biosciences, a biotechnology company developing a new class of therapies to target and selectively destroy cancer cells using viral nanoparticle...
Last Patient Last Visit (LPLV) completed in Phase II Study for the Treatment of Calcific Uraemic Arteriolopathy in End Stage Renal Disease Patients Palma, Spain and San Diego, USA, December 21, 2017 – Laboratoris Sanifit S.L., a clinical-stage biopharmaceutical company focused on treatments for calcification disorders, announced today that the Last Patient’s Last Visit (LPLV) occurred...
Approval granted several months ahead of the initial schedule Launch of HEMOBLAST™ Bellows in the United States expected over the summer in 2018 Saint-Priest, France, December 18, 2017 – Biom’Up, specialist in surgical hemostasis, announces today that it has received FDA marketing approval for HEMOBLASTTM Bellows, its flagship product, 7 months ahead of schedule. This pre-marketing...
Lund, Sweden, 08.00 CET, 13 December 2017 – BONESUPPORT™, an emerging leader in innovative injectable bio-ceramic bone substitute products to treat bone voids caused by trauma, infection, disease or related surgery based on its unique CERAMENT® platform today announces that it has achieved its aim of recruiting 136 patients into the CERTiFy (CERAMENT® Treatment of Fracture defects)...
BURLINGTON, Mass., Dec. 12, 2017 (GLOBE NEWSWIRE) — scPharmaceuticals Inc. (Nasdaq:SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to transform infused therapies, advance patient care and reduce healthcare costs, today announced that Troy A. Ignelzi, chief financial officer of scPharmaceuticals, will present at the BMO Capital Markets Prescriptions for Success Healthcare Conference at 4:30 PM ET on Thursday, December...
1 2 3 6